First U.S. Procedure Completed with Combined Abbott, Stereotaxis Tech

Stereotaxis, a company focused on surgical robotics for minimally invasive endovascular intervention, announced the first U.S. patients were treated using Abbott’s EnSite X EP system with its Robotic Magnetic Navigation system.
 
The integration of Abbott’s cardiac mapping with Stereotaxis’ robotic tech was first revealed at Heart Rhythm 2023. It combines detailed, real-time diagnostic info with robotics’ precision and stability during therapy delivery.
 
The first integrated procedures in the U.S. were completed by physicians at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center.
 
“We are very pleased with how well these initial procedures went and the progress toward open interoperability with robotics in electrophysiology,” Dr. Dhanunjaya Lakkireddy, electrophysiologist and executive medical director of Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center, told the press. “Combining Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology enhances precision and streamlines procedure workflow, ultimately benefiting the patients we are dedicated to treating.”
 
“Abbott and Stereotaxis have each played leading roles in advancing care for the most complex and difficult to treat arrhythmia patients,” added Dr. Jim Cheung, associate director of cardiac electrophysiology at Weill Cornell Medical Center. “We are delighted to be able to use both technologies in an integrated fashion, leveraging the combined benefits in diagnosis and therapy for our patients.”
 
The first procedures internationally using the combined system took place in the Netherlands and Germany in July of this year.